



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2019

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2019

Publication ID:

GMD0319076

Publication Date:

March 29, 2019

Pages:

72

Publisher:

Global Markets Direct

Region:

Global [1]

\$3,500.00

Publication License Type *

Single User License (PDF), \$3,500.00

Site License (PDF), \$7,000.00

Global License (PDF), \$10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H1 2019'; Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages.

The report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H1 2019' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Respiratory, Infectious Disease, Toxicology, Dermatology, Gastrointestinal and Hematological Disorders which include indications Melanoma, Alzheimer's Disease, Lung Disease, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Appendicitis, Chemotherapy Effects, Chemotherapy Induced Neutropenia, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Mycobacterium Infections, Neurology, Peritoneal Cancer, Peritonitis, Radiation

Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development

Aduro BioTech Inc

Bolder Biotechnology Inc

Celdara Medical LLC

Profarma

Savara Inc

Targovax ASA

XL-protein GmbH

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles

BBT-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMJG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVAX Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONCOS-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones

Featured News & Press Releases

Feb 11, 2019: First patient treated in dose expansion cohort of Targovax's ONCOS-102 trial in melanoma

Dec 12, 2018: Targovax presents at DNB 9th Annual Nordic Healthcare Conference

Nov 02, 2018: Savara completes enrolment for Phase IIa Molgradex trial

Oct 24, 2018: Bolder BioTechnology to present preclinical data of BBT-007 at Acute Radiation Syndrome Meeting

Oct 15, 2018: Savara completes enrollment in pivotal Molgradex impala clinical study for the treatment of aPAP

Oct 11, 2018: Targovax key opinion leader symposium on oncolytic viruses in New York city

Oct 01, 2018: Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting

Sep 27, 2018: Savara provides enrollment update on Molgradex Impala and OPTIMA clinical studies and reaffirms guidance for topline data

Sep 27, 2018: Targovax to host key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018

Sep 27, 2018: Targovax announces interim results from phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma

Sep 12, 2018: Targovax announces publication of data on oncolytic virus program ONCOS-102 in the Journal of Medical Virology and Cancer Gene Therapy

Jul 25, 2018: Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF

Jul 16, 2018: Sylvester is One of Four Sites for Clinical Trial to Treat Advanced Colorectal and Ovarian Cancers

Jul 16, 2018: Targovax doses first patient in ONCOS-102 and DCVAC Phase I/II trial

Jul 11, 2018: Ludwig Cancer Research and CRI start Phase I/II trial for cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Aduro BioTech Inc, H1 2019

Pipeline by Bolder Biotechnology Inc, H1 2019

Pipeline by Celdara Medical LLC, H1 2019

Pipeline by Profarma, H1 2019

Pipeline by Savara Inc, H1 2019

Pipeline by Targovax ASA, H1 2019

Pipeline by XL-protein GmbH, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

Companies Mentioned:

Aduro BioTech Inc

Bolder Biotechnology Inc

Celdara Medical LLC

Profarma

Savara Inc

Targovax ASA

XL-protein GmbH

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or

persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL: <https://www.drugpipeline.net/global-markets-direct/granulocyte-macrophage-colony-stimulating--actor-receptor-subunit-alpha-2>

Links

[1] <https://www.drugpipeline.net/region/global>